Regulatory T cell therapies to treat autoimmune diseases and transplant rejection

We are pleased to share that the meeting report from the Fall 2024 workshop co-hosted by the National Institute of Allergy and Infectious Diseases (NIAID) and the Health and Environmental Sciences Institute (HESI) on Regulatory T Cell (Treg) Therapies for Autoimmune Diseases and Transplant Rejection has been published in Nature Immunology.

This expert-driven workshop convened global leaders in immunology, cell therapy, and regulatory science to address key challenges and opportunities in the development of Treg cell therapies. The published report offers a comprehensive summary of current progress and future priorities in the field.

Key themes include:

• Status of clinical studies involving Treg cell therapies
• Advances in engineering approaches to improve therapeutic potential
• Nonclinical safety assessment strategies
• Regulatory considerations and opportunities for early engagement with the FDA
• Identification of five critical areas for community collaboration to accelerate success

We extend our sincere appreciation to the organizing committee, speakers, and all who participated in this impactful event. Your insights and expertise have shaped a valuable resource for advancing Treg cell therapy development.

Read the full report here:
Regulatory T cell therapies to treat autoimmune diseases and transplant rejection. Bluestone et al. 2025. Nature Immunology. https://www.nature.com/articles/s41590-025-02154-2